×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:NTRA

Natera Stock Forecast, Price & News

$36.93
+1.49 (+4.20%)
(As of 07/1/2022 08:45 PM ET)
Add
Compare
Today's Range
$35.14
$37.51
50-Day Range
$28.13
$41.38
52-Week Range
$26.10
$129.09
Volume
743,900 shs
Average Volume
2.02 million shs
Market Capitalization
$3.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$91.40

Natera MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
147.5% Upside
$91.40 Price Target
Short Interest
Bearish
8.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Natera in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$6.32 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($5.78) to ($4.84) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.93 out of 5 stars

Medical Sector

577th out of 1,412 stocks

Medical Laboratories Industry

16th out of 31 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Natera logo

About Natera (NASDAQ:NTRA) Stock

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

NTRA Stock News Headlines

Natera, Inc. (NASDAQ:NTRA) CFO Sells $15,269.52 in Stock
Natera, Inc. (NASDAQ:NTRA) CEO Sells $59,075.52 in Stock
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
2,670
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/04/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$91.40
High Stock Price Forecast
$139.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+147.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
8 Analysts

Profitability

Net Income
$-471.72 million
Pretax Margin
-81.79%

Debt

Sales & Book Value

Annual Sales
$625.49 million
Book Value
$6.91 per share

Miscellaneous

Free Float
86,423,000
Market Cap
$3.56 billion
Optionable
Optionable
Beta
1.21














Natera Frequently Asked Questions

Should I buy or sell Natera stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Natera stock.
View analyst ratings for Natera
or view top-rated stocks.

What is Natera's stock price forecast for 2022?

8 Wall Street analysts have issued 12-month price targets for Natera's shares. Their NTRA stock forecasts range from $54.00 to $139.00. On average, they predict Natera's stock price to reach $91.40 in the next twelve months. This suggests a possible upside of 147.5% from the stock's current price.
View analysts' price targets for Natera
or view top-rated stocks among Wall Street analysts.

How has Natera's stock price performed in 2022?

Natera's stock was trading at $93.39 at the beginning of 2022. Since then, NTRA stock has decreased by 60.5% and is now trading at $36.93.
View the best growth stocks for 2022 here
.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Natera
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings results on Thursday, May, 5th. The medical research company reported ($1.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.05. The medical research company earned $194.13 million during the quarter, compared to analyst estimates of $176.61 million. Natera had a negative net margin of 81.90% and a negative trailing twelve-month return on equity of 96.99%. Natera's revenue for the quarter was up 27.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.74) earnings per share.
View Natera's earnings history
.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $790.00 million-$810.00 million, compared to the consensus revenue estimate of $779.92 million.

Who are Natera's key executives?

Natera's management team includes the following people:

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera CEO Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among Natera's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $36.93.

How much money does Natera make?

Natera (NASDAQ:NTRA) has a market capitalization of $3.56 billion and generates $625.49 million in revenue each year. The medical research company earns $-471.72 million in net income (profit) each year or ($5.880010) on an earnings per share basis.

How many employees does Natera have?

Natera employs 2,670 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for Natera is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.